Synonyms
|
FGF9, FGF-9, Glia-activating factor, GAF, glia-activating factor, HBFG-9, HBGF-9
|
|
|
|
|
Source
|
E.coli-derived mouse FGF-9, Pro3-Ser208, with an N-terminal Met.
|
Molecular Weight
|
|
AA Sequence
|
MPLGEVGSYF GVQDAVPFGN VPVLPVDSPV LLNDHLGQSE AGGLPRGPAV TDLDHLKGIL
RRRQLYCRTG FHLEIFPNGT IQGTRKDHSR FGILEFISIA VGLVSIRGVD SGLYLGMNEK
GELYGSEKLT QECVFREQFE ENWYNTYSSN LYKHVDTGRR YYVALNKDGT PREGTRTKRH
QKFTHFLPRP VDPDKVPELY KDILSQS
|
|
|
|
Sterile Filtered White lyophilized (freeze-dried) powder.
|
Purity
|
>95% by SDS-PAGE and HPLC analyses.
|
Biological Activity
|
The ED50 as determined by thymidine uptake assay using FGF-receptors transfected BaF3 cells is less than0.5 ng/mL, corresponding to a specific activity of > 2.0×106 IU/mg. Fully biologically active whencompared to standard.
|
Endotoxin
|
< 1.0 EU per 1μg of the protein by the LAL method.
|
Formulation
|
Lyophilized from a 0.2 μm filtered concentrated solution in 20 mM Tris, 500 mM NaCl, pH 8.5.
|
Reconstitution
|
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20℃. Further dilutions should be made in appropriate buffered solutions.
|